Polyphor AG

POLYPHOR AG

09/04/2019 07:00

EQS-Adhoc: Polyphor appoints Gökhan Batur as Chief Commercial Officer

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

04/04/2019 07:00

EQS-News: Polyphor to present data on murepavadin and its lead preclinical compound of its novel class of Gram-negative antibiotics at the 29th European Congress of Clinical Microbiology and Infectious Diseases

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

15/03/2019 07:00

EQS-Adhoc: Polyphor announces financial results for the full-year 2018

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

04/02/2019 18:00

EQS-Adhoc: Polyphor awarded grant from CARB-X of up to $5.6M to support development of novel antibiotic against multi-drug resistant Gram-negative pathogens

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

03/12/2018 07:00

EQS-Adhoc: Polyphor announces positive results from the FDA Type B Guidance meeting on the planned Phase III study for balixafortide

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

23/11/2018 07:00

EQS-News: Polyphor wins the Swiss Technology Award 2018

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

24/10/2018 07:05

EQS-Adhoc: Balixafortide combination with eribulin in metastatic breast cancer data presented at ESMO 2018 show consistent positive trend for all efficacy endpoints, including overall survival

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

24/10/2018 07:00

EQS-Adhoc: Polyphor announces protocol agreement with the FDA for the second pivotal Phase III study of murepavadin

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

24/10/2018 06:56

EQS-Adhoc: CMDO Debra Barker to leave Polyphor; Frank Weber to assist in the transition

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

18/10/2018 17:31

EQS-News: Polyphor to present new survival data for balixafortide at the 2018 European Society for Medical Oncology (ESMO) Congress

Voir tous les communiqués de Polyphor AG

«
3
4
5
6
7
8
9
10
»